Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $820.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by Truist Financial from $798.00 to $820.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the stock from $627.00 to $860.00 in a research report on Wednesday. Canaccord Genuity Group boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Citigroup upped their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $791.05.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $796.55 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11. The business has a 50 day simple moving average of $738.12 and a two-hundred day simple moving average of $628.80. The stock has a market capitalization of $83.72 billion, a PE ratio of 19.07, a P/E/G ratio of 2.16 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the company earned $12.46 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Insider Activity

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. PGGM Investments lifted its stake in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after buying an additional 51,900 shares in the last quarter. Founders Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 538 shares in the last quarter. Generate Investment Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $6,300,000. Osaic Holdings Inc. grew its position in shares of Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after purchasing an additional 6,073 shares in the last quarter. Finally, Hudson Value Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $398,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.